Global PLGA (Poly Lactic-co-glycolic Acid) Market Trends and Insights
Rising Demand for Long-Acting Injectable Therapies
The PLGA (poly lactic-co-glycolic acid) market is supported by long-acting injectable therapies that can maintain drug exposure after a single administration. The U.S. Food and Drug Administration had approved 27 PLGA-based long-acting injectable drug products by 2025 across microparticle, solid-implant, and in situ gel formats. Lupin Limited received U.S. Food and Drug Administration approval for risperidone extended-release injectable suspension in September 2025, with 180-day competitive generic therapy exclusivity. Generic entry makes polymer characterization more important because developers must demonstrate comparable release behavior and product performance. Spray-drying research published in 2025 also showed a one-step route for continuous microparticle production with control over particle size, morphology, and release kinetics.Expansion of Bioresorbable Implants and Surgical Materials
The PLGA (poly lactic-co-glycolic acid) market benefits from material adjustment through the lactide-to-glycolide ratio, molecular weight, and end-group chemistry. A 2025 review documented PLGA-based fixation devices, cardiovascular products, tissue-engineering scaffolds, and drug-eluting implants. Evonik Industries AG opened a medical device center in Shanghai in July 2025 with an ISO Class 7 cleanroom for bioresorbable components used across orthopedic, cardiovascular, ophthalmic, dental, and surgical applications. A 2025 study found that patient-specific 3D-printed PLGA implants for hypertelorism surgery achieved a 0.1 mm design deviation. These capabilities can support specialized craniofacial and pediatric procedures where avoiding later metal-removal surgery may be valuable. Device suppliers still need to meet U.S. Food and Drug Administration requirements, European Medical Device Regulation requirements, and ISO 13485 quality-system expectations.Complex Polymerization, Purification, and Scale-Up Requirements
PLGA production uses ring-opening polymerization of lactide and glycolide monomers, and its output is sensitive to temperature, catalyst selection, monomer purity, and moisture. These variables affect molecular weight distribution, end-group chemistry, stereochemical composition, degradation, and release behavior. A 2025 study found that longer microsphere residence time in ethanolic solution during solvent extraction reduced residual ethyl acetate by 93% from the baseline formulation. Such process changes can require extensive revalidation when production moves from laboratory work to commercial volumes. Manufacturers must also control particle size, morphology, drug loading, residual solvents, and release behavior across batches. This raises the qualification hurdle for suppliers seeking to serve regulated pharmaceutical applications.Other drivers and restraints analyzed in the detailed report include:
- Growth of Regenerative Medicine and Tissue Engineering
- Regulatory Familiarity with PLGA-Based Medical Products
- High Production and Quality-Control Costs
Segment Analysis
Microspheres held 36.23% of the PLGA (poly lactic-co-glycolic acid) market share in 2026, reflecting their established role in long-acting injectable formulations. They are used in marketed therapies across oncology, endocrinology, and psychiatry, including leuprolide acetate, octreotide acetate, and triamcinolone acetonide products. Lupin Limited’s September 2025 approval for risperidone extended-release injectable suspension showed continuing generic activity in complex microsphere products. This activity can increase demand for consistent pharmaceutical-grade polymer as competing developers work to achieve comparable performance.Nanoparticles are projected to advance at a 13.54% CAGR through 2032, making them the fastest-growing product form in the PLGA (poly lactic-co-glycolic acid) industry. Their small size supports work in drug co-delivery, diagnostic imaging, and nucleic-acid encapsulation. A 2025 Scientific Data dataset included 433 PLGA nanoparticle formulations covering 65 small molecules. Evonik Industries AG published a U.S. patent application in August 2025 for PLGA-based polynucleotide delivery particles that combine PLGA with cationic lipids. The PLGA (poly lactic-co-glycolic acid) market also includes in situ forming matrices and hydrogels for intra-articular and intraocular delivery.
The medical segment held 75.65% of the PLGA (poly lactic-co-glycolic acid) market size in 2026 and is projected to advance at a 13.81% CAGR through 2032. Drug delivery, surgical implants, and regenerative medicine provide several routes for medical demand rather than relying on a single clinical category. The material can be used in drug-eluting implants and bioresorbable fixation devices that contain therapeutic agents. The mature regulatory history for PLGA in both drug and device uses can simplify the material case within a broader development plan. Pharmaceutical-grade suppliers must still meet current good manufacturing practice standards and quality documentation requirements.
Non-medical applications account for the remaining revenue and include agriculture, packaging, and textiles. Agrochemical encapsulation can use hydrolytic release to extend the delivery of pesticides and fertilizers. This can reduce application frequency and limit unnecessary environmental loading when product performance is validated. Packaging and textile use face more difficult cost comparisons with polylactic acid and polycaprolactone. The PLGA (poly lactic-co-glycolic acid) market remains weighted toward applications where performance, regulatory evidence, and controlled degradation are more important than polymer price alone.
Complete Report Scope:
- By Product Form
- Microspheres
- Nanoparticles
- Films
- Other Product Forms
- By Application
- Medical
- Non-Medical
- By Processibility
- Extrusion
- Injection Molding
- Electrospinning
- Other Processibilities
- By End-Use Industry
- Pharmaceutical Manufacturing
- Healthcare
- Biotechnology Firms
- Packaging
- Textile
- Agriculture
- Other End-Use Industries
- By Geography
- Asia-Pacific
- China
- India
- Japan
- South Korea
- ASEAN Countries
- Rest of Asia-Pacific
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- NORDIC Countries
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- South Africa
- Rest of Middle East and Africa
- Asia-Pacific
Geography Analysis
North America held 38.08% of the PLGA (poly lactic-co-glycolic acid) market share in 2026, supported by pharmaceutical and biotechnology research activity in the United States. The region has a substantial base of U.S. Food and Drug Administration-approved long-acting injectable products and regulated medical-device development. Lupin Limited received U.S. Food and Drug Administration approval for risperidone extended-release injectable suspension in September 2025, adding a generic entrant to a complex injectable category. Canada’s contract development and manufacturing capacity and Mexico’s links to North American pharmaceutical supply chains add to regional demand. U.S. regulatory guidance on complex injectables and International Council for Harmonisation residual-solvent requirements define a demanding quality floor for the regional supply base.Asia-Pacific is projected to advance at a 14.04% CAGR through 2032, driven by China’s domestic pharmaceutical manufacturing and emerging bioresorbable medical-device base. Evonik Industries AG opened its largest medical device center in Shanghai in July 2025 to process bioresorbable components for customers across Asia. India’s contract development and manufacturing sector supports demand linked to generic long-acting injectable programs. Japan and South Korea add demand through the pharmaceutical and orthopedic-device markets. The Association of Southeast Asian Nations (ASEAN) countries remain early-stage adopters as healthcare infrastructure develops.
Corbion N.V. is headquartered in the Netherlands, while Seqens has operations in France and GMP manufacturing in Devens, United States, and Aramon, France. Evonik Industries AG appointed IMCD as the exclusive European distributor for RESOMER bioresorbable polymers for implantable medical-device uses in July 2025. European Medical Device Regulation requirements and European Medicines Agency familiarity with PLGA products support demand for certified grades. South America and the Middle East and Africa hold smaller positions, while Brazil and Saudi Arabia offer potential as pharmaceutical production and healthcare investment expand.
List of Companies Covered in this Report:
- Akina, Inc.
- Ashland
- Bezwada Biomedical, LLC
- CD Bioparticles
- Corbion N.V.
- Creative PEGWorks
- Evonik Industries AG
- Jinan Daigang Bioengineering Co., Ltd.
- Merck KGaA
- Mitsui Chemicals, Inc.
- Nomisma Healthcare Pvt. Ltd.
- Poly-Med Incorporated
- Polysciences
- Seqens
- Shandong Keyuan Pharmaceutical Co., Ltd.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Akina, Inc.
- Ashland
- Bezwada Biomedical, LLC
- CD Bioparticles
- Corbion N.V.
- Creative PEGWorks
- Evonik Industries AG
- Jinan Daigang Bioengineering Co., Ltd.
- Merck KGaA
- Mitsui Chemicals, Inc.
- Nomisma Healthcare Pvt. Ltd.
- Poly-Med Incorporated
- Polysciences
- Seqens
- Shandong Keyuan Pharmaceutical Co., Ltd.

